文献速递头颈外科

复发或转移性头颈部鳞状细胞癌的一线治疗:一项回顾性、多中心、真实世界研究

First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study.
PubMed 文献 · Head Neck · 2025-06-10

该回顾性多中心真实世界研究分析了2021年1月至2023年12月在法国南锡和里尔两个中心接受一线治疗的290例复发或转移性头颈部鳞状细胞癌患者,比较了帕博利珠单抗单药、帕博利珠单抗联合化疗、TPEx方案及调整方案的无进展生存期和总生存期,发现各组间存在显著差异,帕博利珠单抗联合化疗为 preferred 治疗选择。

要点

  • 290例患者中,19%接受帕博利珠单抗单药,28%接受帕博利珠单抗联合化疗,19%接受TPEx,20%接受调整方案。
  • 中位无进展生存期:帕博利珠单抗单药2.9个月,联合化疗6个月,TPEx 5.9个月,调整方案4.3个月。
  • 中位总生存期:帕博利珠单抗单药9.4个月,联合化疗15.5个月,TPEx 13.7个月,调整方案10个月。

核心结论

  • 帕博利珠单抗联合化疗是复发或转移性头颈部鳞状细胞癌的首选治疗选择。

研究设计与样本

  • 回顾性、多中心、真实世界研究,纳入2021年1月至2023年12月在法国南锡和里尔接受一线治疗的290例复发或转移性头颈部鳞状细胞癌患者。

主要发现

  • 各组无进展生存期和总生存期存在显著差异。
  • 中位无进展生存期:帕博利珠单抗单药2.9个月,帕博利珠单抗联合化疗6个月,TPEx 5.9个月,调整方案4.3个月。
  • 中位总生存期:帕博利珠单抗单药9.4个月,帕博利珠单抗联合化疗15.5个月,TPEx 13.7个月,调整方案10个月。
  • 帕博利珠单抗单药是最安全的方案。

关键数值与推荐

  • 在欧洲,帕博利珠单抗联合或不联合化疗是CPS≥1的复发或转移性头颈部鳞状细胞癌的推荐一线治疗。
  • 在法国,CPS<1时首选TPEx方案。

临床怎么用

  • 帕博利珠单抗联合化疗是首选治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Europe, pembrolizumab with or without chemotherapy is the recommended first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1. These regimens were studied in selected populations, which may not reflect real-world patients. METHODS: We reviewed all R/M HNSCC cases treated with first-line regimens between January 2021 and December 2023 in Nancy and Lille. Data on patient history, treatments, survival, response, and safety were collected. PFS and OS were analyzed using the Cox multivariable regression model, adjusting for the covariates age, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, and nutritional status. RESULTS: The analysis included 290 patients; 19% received pembrolizumab alone, 28% received pembrolizumab with chemotherapy, 19% received TPEx, and 20% received adapted regimens. PFS and OS differed significantly between groups. Median PFS and OS were respectively 2.9 and 9.4 months for pembrolizumab, 6 and 15.5 months for pembrolizumab-chemotherapy, 5.9 and 13.7 months for TPEx, and 4.3 and 10 months for adapted regimens. Pembrolizumab alone is the safest regimen. CONCLUSION: This retrospective study reflects real-world first-line therapy for R/M HNSCC in two French cancer institutes. Pembrolizumab combined with chemotherapy is the preferred treatment option.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Simon A, Abdeddaim C, Nguyen D, et al. First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study. Head Neck. 2025. PMID: 40491285. doi:10.1002/hed.28211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。